Cardinal Health earnings and capital return in focus Cardinal Health (CAH) has drawn fresh attention after releasing its fourth quarter and full year 2026 results, paired with a new US$5b share repurchase authorization and a confirmed quarterly dividend. The latest numbers give you an updated view of how the healthcare distributor is converting its large revenue base into profit and cash flow. They also show how management is choosing to return capital to shareholders through buybacks and...

On August 11, Cardinal Health (NYSE:CAH) reported fourth-quarter fiscal 2026 results that on the surface look almost too good to be true. Non-GAAP diluted EPS jumped 40% year over year to $2.91, and full-year adjusted free cash flow hit $5 billion. But a large piece of that quarterly jump came from a one-time tariff refund, […]

Cardinal Health's (CAH) vertical integration of "higher-growth and higher-margin services" will comp

Moderna upgraded, Baidu downgraded: Wall Street's top analyst calls

Markets turned south again Wednesday as surging yields and geopolitical fears rattled investors, but Wall Street analysts spotted opportunity and danger in names like Baidu, Klarna, Honeywell Aerospace, and Dollar Tree that traders need to see before the open.

OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.

GLP-1 tailwinds and specialty strength drove pharma profit up 21% in Q4.

Anita Zielinski will join Cardinal Health in November as its new chief accounting officer.

Cardinal Health’s second quarter results reflected strong profit growth, despite revenue falling short of Wall Street’s expectations. Management credited broad-based demand in its Pharmaceutical and Specialty Solutions segment, stable operating margins, and continued progress on its improvement plan in the Global Medical Products and Distribution unit as key performance drivers. CFO Aaron Alt called out “strong demand, strong execution, strong profit,” highlighting the company’s ability to deliv

Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.

HNGE's strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.

Solventum plans to spin off its $1.4B HIS business, sharpening its MedTech focus while giving HIS more flexibility to pursue growth.

CVS Health advances its $20 billion technology push with AI tools, Health100 and automation aimed at simplifying care and improving engagement.

Healthcare distributor and services company Cardinal Health (NYSE:CAH) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 5.8% year on year to $63.67 billion. Its non-GAAP profit of $2.60 per share was 7.4% above analysts’ consensus estimates.

Here is how BioMarin Pharmaceutical (BMRN) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Monolithic Power Systems is benefiting from surging AI demand, while Las Vegas Sands faces earnings pressure and a prolonged downtrend.

Keurig Dr Pepper has recently reported second-quarter 2026 results showing sales of US$7.31 billion and net income of US$142 million, while rolling out a lime-led reformulation of 7UP and partnering with Portillo’s on limited-time Dr Pepper shakes in the U.S. Alongside these product moves, the company has added Cardinal Health CFO Aaron Alt to its board as it works through a planned split into separate beverage and coffee businesses. With Aaron Alt joining the board during Keurig Dr Pepper’s...

Cardinal Health (CAH) gave investors plenty to like in its fiscal fourth-quarter report this week, sending shares to a record high of $258 as Wall Street digests another earnings beat and an encouraging FY27 outlook.

RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.

BWXT expands its commercial nuclear portfolio through nuclear medicine, isotope production and radiopharmaceutical capabilities.

Cooper Companies' premium lens migration, MiSight growth and fertility recovery offer long-term upside despite Asia-Pacific, tariff and FX pressures.

After a very strong multi year run, Cardinal Health stock is now being judged by a low overall value score and fresh questions about risk controls, so investors are weighing whether the current price still fairly reflects its fundamentals. Cardinal Health has delivered about 409.2% over the past 5 years, which sets expectations high for what comes next. The recent levothyroxine tablet recalls and the appointment of a new Chief Accounting Officer may affect how the market prices Cardinal...

Cardinal Health targets 13%-15% fiscal 2027 EPS growth as pharma demand normalizes and specialty, At-Home and buybacks remain key priorities for execution.

Companies In The Article Are:FRMI,CAH,PLUG and ARMK

Cardinal Health Inc (CAH) delivered a stellar Q4 with 40% EPS growth, driven by strong segment performance and a $5 billion free cash flow year.

AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.

Healthcare distributor and services company Cardinal Health (NYSE:CAH) will be announcing earnings results this Tuesday before market hours. Here’s what to expect.

Moby summary of Cardinal Health, Inc.'s Q4 2026 earnings call

Cardinal Health (NYSE:CAH) reported fourth-quarter fiscal 2026 results marked by growth in revenue, operating earnings and adjusted earnings per share, supported by demand in its pharmaceutical and specialty businesses and a one-time tariff-related benefit in its medical products segment. For the q

Cardinal Health beats fiscal Q4 EPS estimates as profit surges, while revenues miss; fiscal 2027 guidance points to continued earnings growth.

RadNet tops Q2 estimates as advanced imaging and Digital Health growth accelerate, prompting a higher 2026 Imaging Center outlook.

Existing Home Sales Data in Focus

We don't expect much movement either direction until inflation reports begin to hit the tape Wednesday morning.

AdaptHealth (NASDAQ:AHCO) executives outlined the company’s second-quarter performance, portfolio changes and plans to focus capital on sleep, respiratory and home medical equipment businesses during a Canaccord conference discussion. Chief Executive Officer Suzanne Foster said the company has spen

Although the revenue and EPS for Cardinal (CAH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

S&P 500 drug distributor Cardinal Health easily topped fiscal fourth-quarter earnings forecasts despite a revenue shortfall. Rival McKesson, which whipsawed after its earnings report last week, has climbed back near a buy point. Cencora, another big S&P 500 drug distributor, also is near a buy point, but MCK stock may be the strongest of the three.

Cardinal Health stock rose slightly early Tuesday on better-than-expected fiscal fourth-quarter earnings, but sales missed.

Cardinal Health Inc. (NYSE:CAH) shares advanced in pre-market trading on Tuesday after the healthcare company delivered better-than-expected fourth-quarter earnings and issued fiscal 2027 profit guidance above Wall Street forecasts.

Cardinal (CAH) delivered earnings and revenue surprises of +20.25% and -2.96%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

US equity markets were mostly trending higher before the open Tuesday as investors weigh fading opti

Cardinal Health reports mixed quarterly performance across its business segments as earnings get a lift from one-time tariff refunds.

Cardinal Health had a mixed fiscal fourth quarter in terms of sales across its two main business lines, but expects revenue to rise in both segments in the new fiscal year.

Healthcare distributor and services company Cardinal Health (NYSE:CAH) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 5.8% year on year to $63.67 billion. Its non-GAAP profit of $2.91 per share was 20.2% above analysts’ consensus estimates.

Today Economic data: NFIB small-business index for July, existing home sales Earnings: Cardinal Health, Lumentum, CoreWeave, Super Micro, On Holding, Smithfield Foods Wednesday Inflation data: Consumer price index for July, 8:30 a.

QuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.

ITGR beats Q2 earnings and revenue estimates, but sales and margins decrease as product headwinds persist ahead of its $5.7B KKR deal.

INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.

IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.